



## **Supplemental Data**

### **Endothelial FABP4 constitutes the majority of basal circulating hormone levels and regulates lipolysis-driven insulin secretion**


Karen E. Inouye, Kacey J. Prentice, Alexandra Lee, Zeqiu B. Wang, Carla Dominguez-Gonzalez, Mu Xian Chen, Jillian K. Riveros, M. Furkan Burak, Grace Y. Lee, Gökhan S. Hotamışlıgil




**Supplementary Figure 1. Breeding scheme and construct design for tissue-specific FABP4 deletion mice.** (A) Mice with floxed humanized *Fabp4* (*hFabp4* flox/flox) were crossed with Adiponectin-Cre, Tek-Cre, LyzM-Cre, or CMV-Cre mice to generate mice with deletion of FABP4 in adipocytes (Adipo-KO), endothelial cells (Endo-KO), myeloid cells (Myeloid-KO), or the whole body (Total-KO). Since crossing with CMV-Cre produces germline deletion of *hFabp4*, CMV-Cre was bred out of the majority of the Total-KO mice used for these studies. *hFabp4* flox mice are referred to as WT. WT mice used in this study are littermates of Adipo and Endo-KO mice that did not express Cre recombinase. (B) The mouse *Fabp4* gene was first humanized by substituting the 11 amino acids differing between mouse and human *FABP4* located in exons 2 and 3. (C) Exon 2 was flanked at the 3' end by a FRT-neomycin-FRT-loxP cassette and by a single loxP site at the 5' end. The distal loxP site was positioned upstream of exon 2 within the intron 1 sequences. The model was generated by homologous recombination in embryonic stem cells. The FRT-flanked selection cassette was removed in vivo by crossing with Flp-recombinase-expressing mice. Dark gray rectangles represent *Fabp4* coding sequences. Light gray rectangles indicate non-coding exon portions. Solid lines represent chromosome sequences. The 11 murine/human amino acid substitutions are represented by stars.




**Supplementary Figure 2. FABP4 is deleted from macrophages of Endo-KO mice.** Peritoneal macrophage lysate FABP4 levels from WT and Endo-KO mice. \*\*\*\* $P < 0.0001$  by unpaired t-test.





**Supplementary Figure 3. Validation of tissue-specific deletion of FABP4 from adipocytes.** (A) Representative immunoblots (n=2) and quantification of FABP4 protein relative to beta-tubulin loading control in mesenteric adipose tissue of WT, Adipo-KO, Endo-KO, and Total-KO mice. WT, Total-KO: n=5/group; Adipo-KO, Endo-KO: n=6/group. (B) Immunoblot and quantification of FABP4 expression relative to beta-tubulin loading control in brown adipose tissue of WT, Adipo-KO, Endo-KO, and Total-KO mice. n=3/group. (C) Representative FABP4 immunostaining in brown adipose tissue from WT, Adipo-KO, Endo-KO, and Total-KO mice. 40X magnification. (D) Representative FABP4 immunostaining in perigonadal adipose tissue (PGWAT) from *Fabp4/5<sup>-/-</sup>* mice. 40X magnification. \* $P < 0.05$ , \*\* $P < 0.01$  by 1-way ANOVA, followed by Tukey's multiple comparison test. ND: No signal detected.



**Supplementary Figure 4. FABP4 is decreased in brown adipose tissue of Myeloid-KO mice.** Immunoblots and quantification of FABP4 protein relative to beta-tubulin loading control in (A) mesenteric and (B) brown adipose tissue of WT and Myeloid-KO mice. n=5/group. \* $P < 0.05$  by unpaired t-test.




**Supplementary Figure 5. FABP5 is increased in perirenal adipose of Total-KO mice.** Representative immunoblot (n=2) and quantification of perirenal adipose FABP5 protein relative to beta-tubulin loading control in WT, Adipo-KO, Endo-KO, and Total-KO mice. WT, Adipo-KO, Endo-KO: n=5/group. Total-KO: n=4. Recombinant hexahistidine-tagged FABP5, which travels at 19 kDa, was used as a positive control. *Fabp5*<sup>-/-</sup> adipose lysate was a negative control. \**P* < 0.05, \*\**P* < 0.01 by 1-way ANOVA, followed by Dunnett's multiple comparison test.




**Supplementary Figure 6. 88.5% of liver CD31-isolated cells are endothelial cells, and FABP4 protein signal in liver comes from endothelial cells.** (A) FACS analysis of WT liver endothelial cells isolated with anti-CD31 antibody-coated beads, and co-stained with anti-CD31-FITC and anti-F4/80-APC to determine the percentage of F4/80-positive macrophages within the CD31 population. From n=1 WT mouse. (B) Immunoblots of FABP4 protein and beta-tubulin loading control in liver lysates from WT, Endo-KO, and Total-KO mice. WT: n=3. Endo-KO, Total-KO: n=2/group. Lysates from perigonadal adipose (PGWAT) of WT mice included as a positive control.

## Females




**Supplementary Figure 7. Baseline and lipolysis-source FABP4 in females is similar to males.** (A) 6h daytime fasted plasma FABP4 levels and (B) body weights of lean ~12 week-old female WT, Adipo-KO, Endo-KO, and Total-KO mice from S7D lipolysis experiment. n=8/group. (C) Body weights of males from Figure 3A 6h fasting FABP4 levels. WT (n=43), Adipo-KO (n=29), Endo-KO (n=29), and Total-KO (n=23) (D) Absolute and (E) baseline-corrected plasma FABP4 responses to 10mg/kg isoproterenol-induced lipolysis in female WT, Adipo-KO, and Endo-KO mice. n=8/group. \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , \* $P < 0.05$  vs. WT;  $^{\circ\circ\circ}P < 0.0001$ ,  $^{\circ\circ}P < 0.001$  vs. Endo-KO, by 1-way ANOVA (A - C) or mixed-effects model (D, E), followed by Tukey's multiple comparison test.






**Supplementary Figure 8. FABP5 levels are not changed in Endo-KO mice.** (A) FABP5 levels in overnight conditioned media and (B) lysates of CD31-isolated endothelial cells from liver, spleen, heart, and lung of WT and Endo-KO mice. Lysates were from freshly isolated cells.



**Supplementary Figure 9.** Light microscopy image of HUVECs at days 4 and 11 post-seeding. Day 11 HUVECs demonstrate "cobblestone" phenotype. 10X magnification.



**Supplementary Figure 10. Isoproterenol inhibits islet insulin secretion.** Insulin secretion from isolated islets of WT, Adipo-KO, and Endo-KO mice in response to low glucose (LG, 2.8mM), high glucose (HG, 16.7mM), high glucose + isoproterenol (ISO, 10 $\mu$ M). Insulin secretion is normalized to cellular DNA. n=3 males, n=3 females per group. \* $P < 0.05$ , \*\* $P < 0.005$  by 1-way ANOVA, followed by Tukey's multiple comparison test.

**Supplementary Table 1: Agents that did not affect HUVEC FABP4 secretion**

		<b>Reagent</b>
<b>Secretory Mechanisms</b>	<b>ER-Golgi pathway inhibition</b>	Brefeldin A, monensin (Up to 20uM)
	<b>Lysosomal pathway inhibition</b>	Chloroquine (Up to 50uM)
		NH <sub>4</sub> Cl (Up to 50mM)
<b>Increased intracellular Ca<sup>++</sup></b>	Histamine (Up to 25uM)	
<b>Stimuli</b>	<b>Lipolytic/Adrenergic</b>	FSK (Up to 25uM), IBMX (1mM) CL-316,243 (Up to 20uM) Isoproterenol (Up to 50uM)

Day 12 HUVECs were treated for 2 hours with agents known to target secretory mechanisms in adipocytes and endothelial cells, and stimulate adipocyte FABP4 secretion.